A case of severe anemia induced by ensartinib, anlotinib, pemetrexed and zoledronic acid

Published on Sep. 12, 2023Total Views: 1482 times Total Downloads: 525 times Download Mobile

Author: Ting-Ting ZHENG ¹ Xiao-Fang WANG ² Yu XU ² Wei ZHANG ¹  Jian-Cun ZHEN ¹

Affiliation: 1. Department of Pharmacy, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China 2. Department of Respiratory and Critical Care Medicine, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China

Keywords: Ensartinib Anlotinib Pemetrexed Zoledronic acid Severe anemia Adverse drug reactions

DOI: 10.19960/j.issn.1005-0698.202309014

Reference: Ting-Ting ZHENG, Xiao-Fang WANG, Yu XU, Wei ZHANG, Jian-Cun ZHEN.A case of severe anemia induced by ensartinib, anlotinib, pemetrexed and zoledronic acid[J].Yaowu Liuxingbingxue Zazhi,2023, 32(9):1071-1075.DOI: 10.19960/j.issn.1005-0698.202309014.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A 42-year-old male patient with stage IV right lung adenocarcinoma was diagnosed for 9 years, and he was treated with multiple chemotherapy and targeted drugs. Due to disease progression, the targeted therapy was adjusted to ensartinib hydrochloride capsules combined with anlotinib, pemetrexed disodium and zoledronic acid. After 82 days of continuous administration of ensartinib, the patient had sudden fatigue without obvious inducement, and the hemoglobin decreased from 132 g·L^-1 before the administration of ensartinib to 59 g·L^-1. The patient was diagnosed as severe anemia, which was considered to be related to ensartinib, anlotinib, pemetrexed and zoledronic acid, and the association of adverse reactions was evaluated as "possible". After drug withdrawal and symptomatic support treatment, the hemoglobin recovered to 97 g·L^-1 on the 6th day of admission. Ensartinib has been approved for marketing in China for a short time, and there are few reports of severe anemia. Reminder of this case, key attention should be paid to some drugs with limited use experience in clinical treatment, in order to find some adverse reactions with low incidence.

Full-text

Please download the PDF version to read the full text: download

References

1.Childress MA, Himmelberg SM, Chen H, et al. ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties[J]. Mol Cancer Res, 2018, 16(11): 1724-1736. DOI: 10.1158/1541-7786.mcr-18-0171.

2.国家药品监督管理局. 国家药监局批准盐酸恩沙替尼胶囊上市[EB/OL]. (2020-11-20) [2022-07-26]. https://www.nmpa.gov.cn/yaopin/ypjgdt/20201120154321135.html.

3.国家药品监督管理局安全监管司, 国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[EB/OL]. (2011-05-04) [2022-07-26]. https://gkml.samr.gov.cn/nsjg/bgt/202106/t20210629_331741.html.

4.王可, 李娟, 孙建国, 等. 间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议（2021年版）[J]. 中国肺癌杂志, 2021, 24(12): 815-828. [Wang K, Li J, Sun JG, et al. Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 Version)[J]. Chinese Journal of Lung Cancer, 2021, 24(12): 815-828.] DOI: 10.3779/j.issn.1009-3419.2021.102.32.

5.Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial[J]. Lancet Respir Med, 2020, 8(1): 45-53. DOI: 10.1016/S2213-2600(19)30252-8.

6.Horn L, Wang Z, Wu G, et al. Ensartinib vs Crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial[J]. JAMA Oncol, 2021, 7(11): 1617-1625. DOI: 10.1001/jamaoncol.2021.3523.

7.张力, 杨云鹏. 恩沙替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌专家共识[J]. 中华肿瘤杂志, 2022, 44(4): 297-306. [Zhang L, Yang YP. Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Chinese Journal of Oncology, 2022, 44(4): 297-306.] DOI: 10.3760/cma.j.cn112152-20220113-00033.

8.Soria JC, Tan D, Chiari R,el al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929. DOI: 10.1016/s0140-6736(17) 30123-x.

9.Peters S, Camidge DR, Shaw AT, el al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 829-838. DOI: 10.1056/nejmoa1704795.

10.唐亚娟, 孙涛, 张婕,等.安罗替尼治疗晚期肿瘤的相关不良事件分析[J]. 药物流行病学杂志, 2021, 30(10): 674-678. [Tang YJ, Sun T, Zhang J, et al. Analysis of related adverse events of amlotinib in the treatment of advanced tumors. Chinese Journal of Pharmacoepidemiology, 2021, 30(10): 674-678.] DOI: 10.19960/j.cnki.issn1005-0698.2021.10.006.

11.Miyahara T, Sueoka-Aragane N, Iwanaga K, et al. Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer[J]. Med Oncol, 2017, 34(12): 195. DOI: 10.1007/s12032-017-1053-8.

12.Coleman R, Burkinshaw R, Winter M,et al. Zoledronic acid[J]. Expert Opin Drug Saf, 2011, 10(1): 133-145. DOI: 10.1517/14740338.2011.540387.

13.中国临床肿瘤学会肿瘤相关性贫血专家委员会. 肿瘤相关性贫血临床实践指南(2015-2016 版)[J]. 中国实用内科杂志, 2015, 11(35): 921-930. DOI: 10.7504/nk2015100202.

14.Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature[J]. Am J Med, 2004, 116(Suppl 7A): 11S-26S. DOI: 10.1016/j.amjmed.2003.12.008.

15.National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) Version 4.0[EB/OL]. (2009-05-29) [2022-07-26]. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf

16.中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J].中国肿瘤临床, 2019, 46(17): 869-875. DOI: 10.3969/j.issn.1000-8179. 2019.17.919.